Related Experiment Videos
Pelvic exenteration for recurrent endometrial cancer
R R Barakat1, N A Goldman, D A Patel
1Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA.
Gynecologic Oncology
|September 30, 1999
Summary
Pelvic exenteration for recurrent endometrial cancer offers a slim chance of cure, despite high complication rates. This radical surgery is a last resort for select patients with central recurrence.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Recurrent endometrial carcinoma presents significant treatment challenges.
- Pelvic exenteration is a complex surgical procedure with limited established curative value in this context.
Purpose of the Study:
- To evaluate the efficacy and outcomes of pelvic exenteration in patients with recurrent endometrial adenocarcinoma.
- To assess the survival rates and complication profile associated with this procedure.
Main Methods:
- Retrospective review of 44 patients who underwent pelvic exenteration for recurrent endometrial adenocarcinoma between 1947 and 1994.
- Analysis included patient demographics, prior treatments (surgery, radiotherapy), exenteration type, postoperative complications, and survival data.
Main Results:
- Major postoperative complications occurred in 80% of patients.
- Median survival was 10.2 months, with 20% achieving long-term survival (>5 years).
- The procedure was performed as total, anterior, or posterior exenteration.
Conclusions:
- Pelvic exenteration for recurrent endometrial cancer is associated with high morbidity and poor overall survival.
- Despite the risks, it remains a potentially curative option for carefully selected patients with central recurrence who have exhausted other treatment modalities.